Phase 3
Completed N=306
Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin Dependence · Opioid-Related Disorders
Source: ClinicalTrials.gov NCT00218426 ↗
Enrolled (actual)
306
Serious AEs
0.3%
Results posted
Feb 2019
Primary outcomePrimary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants
◆ Published Evidence
Established
91citations · ~9 / year
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Summary
Heroin addiction is a growing problem in Russia; individuals who enter heroin addiction treatment often relapse. Therefore, effective heroin addiction treatments are necessary to prevent relapse. The purpose of this study is to compare oral naltrexone with a naltrexone implant that provides opioid blockade for two months in preventing relapse to heroin addiction in St. Petersburg, Russia.
Linked Publications (2)
-
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
-
Sustained-release naltrexone for opioid dependence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Retention Without Relapse to Heroin Addiction (Measured at Month 6) |
54; 16; 11 | — |
| SECONDARY Number of Subjects Who Dropped Out of Treatment |
54; 16; 11 | — |
| SECONDARY Positive Opioid Urine Test |
.427; .636; .341 | — |
| SECONDARY Use of Alcohol |
10.2; 9.0; 9.6 | — |
| SECONDARY Composite Score of Psychiatric Problems |
0.19; 0.15; 0.18 | — |
| SECONDARY HIV Risk (Baseline) |
8.1; 8.0; 8.7 | — |
| SECONDARY Global Assessment Form (GAF) |
62.8; 64.7; 62.5 | — |
| SECONDARY Amphetamine Drug Use |
6; 12; 18 | — |
| SECONDARY Cocaine Drug Use |
0; 0; 0 | — |
| SECONDARY Marijuana Drug Use |
22; 35; 25 | — |
| SECONDARY Benzodiazepine Drug Use |
10; 15; 9 | — |
Eligibility Criteria
Inclusion Criteria
- Current opioid dependence
- Recently completed opioid detoxification
Exclusion Criteria
- Serious medical or psychiatric condition requiring immediate hospitalization or that would make participation in the study hazardous
- Planning to leave the study area within the 12 months following study entry
- Imminent incarceration
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT00218426) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.